Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrahypofractionation of localized prostate cancer-an updated statement of the prostate cancer working group of the German Society of Radiation Oncology (DEGRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

[From limited options to individualized strategies: advances in the treatment of bladder cancer].

Urologie (Heidelberg, Germany)·2026
Same author

Biomarkers in prostate cancer: current status and future directions in radiotherapy-statement from the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same author

[The metastatic and advanced upper tract urothelial carcinoma-a separate entity or bladder cancer's younger sibling?]

Urologie (Heidelberg, Germany)·2024
Same author

The risk of second malignancies following prostate cancer radiotherapy in the era of conformal radiotherapy: a statement of the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2024
Same author

[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].

Urologie (Heidelberg, Germany)·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 25, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

[Radiotherapy in node-positive prostate cancer].

D Bottke1, D Bartkowiak2, C Bolenz3

  • 1Fachbereich Strahlentherapie und Radioonkologie, MVZ Klinikum Esslingen GmbH, Hirschlandstraße 97, 73730, Esslingen a. N., Deutschland. d.bottke@klinikum-esslingen.de.

Der Urologe. Ausg. A
|February 20, 2016
PubMed
Summary
This summary is machine-generated.

Radiotherapy, with or without long-term androgen deprivation therapy (ADT), shows promise for node-positive prostate cancer. Aggressive treatment may lead to long-term survival, but more randomized trials are needed.

Keywords:
Androgen deprivation therapyLymphatic metastasesPositron-emission tomographyProstatectomy, radicalRadiotherapy, adjuvant

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Experiment Videos

Last Updated: Mar 25, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urologic Oncology

Background:

  • Limited data exist for node-positive prostate cancer management, creating treatment uncertainty.
  • Current guidelines suggest androgen deprivation therapy (ADT) alone or with radiotherapy.
  • Node-positive prostate cancer management requires further investigation.

Purpose of the Study:

  • To review radiotherapy's role in definitive, adjuvant, and salvage treatment for node-positive prostate cancer.
  • To discuss PET imaging tracers for biochemical recurrence after prostatectomy.
  • To evaluate radiotherapy's impact on survival in node-positive prostate cancer.

Main Methods:

  • Literature review of retrospective studies and clinical guidelines.
  • Analysis of treatment outcomes for radiotherapy in node-positive prostate cancer.
  • Discussion of patient selection criteria for adjuvant radiotherapy.

Main Results:

  • Retrospective data suggest ADT plus radiotherapy improves survival over ADT alone for definitive treatment.
  • Many node-positive prostate cancer patients may achieve long-term survival with aggressive therapy.
  • Adjuvant radiotherapy benefits patients with pN1 prostate cancer, particularly those with specific tumor characteristics like 3-4 positive lymph nodes or high-grade disease.

Conclusions:

  • Randomized trials are essential to confirm radiotherapy's role in definitive and adjuvant settings for node-positive prostate cancer.
  • Further research is needed to optimize treatment strategies for this patient group.
  • Aggressive therapeutic approaches, including radiotherapy, show potential for curable outcomes.